Next Article in Journal
Alterations of Nuclear Architecture and Epigenetic Signatures during African Swine Fever Virus Infection
Next Article in Special Issue
The Role of Electron Microscopy in Studying the Continuum of Changes in Membranous Structures during Poliovirus Infection
Previous Article in Journal
Determinants of Disease Phenotype Differences Caused by Closely-Related Isolates of Begomovirus Betasatellites Inoculated with the Same Species of Helper Virus
Previous Article in Special Issue
Flaviviral Replication Complex: Coordination between RNA Synthesis and 5’-RNA Capping
Article Menu

Export Article

Open AccessReview
Viruses 2015, 7(9), 4960-4977; doi:10.3390/v7092854

Anti-HBV Drugs: Progress, Unmet Needs, and New Hope

1,†
,
1,†
,
2
,
3
,
1
and
1,*
1
Department of Clinical Pharmacy, Shanghai First People's Hospital, Shanghai Jiao Tong University, 650 New Songjiang Road, Songjiang District, Shanghai 201620, China
2
Department of Pharmacy, Ningbo Medical Treatment Center Lihuili Hospital, 57 Xingning Road, Ningbo 315040, China
3
Department of Pharmacy, The Third Staff Hospital of Baogang Group, 15 Qingnian Road, Baotou 014010, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: David Boehr
Received: 30 April 2015 / Revised: 18 August 2015 / Accepted: 24 August 2015 / Published: 15 September 2015
View Full-Text   |   Download PDF [1875 KB, uploaded 15 September 2015]

Abstract

Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver diseases, including cirrhosis and hepatocellular carcinoma, because we are unable to eliminate chronic HBV infection. Available therapies for chronic HBV infection mainly include nucleos/tide analogues (NAs), non-NAs, and immunomodulatory agents. However, none of them is able to clear chronic HBV infection. Thus, a new generation of anti-HBV drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection. This review aims to summarize the state of the art in new HBV drug research and development and to forecast research and development trends and directions in the near future. View Full-Text
Keywords: hepatitis B virus; anti-HBV drugs; research and development; guidelines hepatitis B virus; anti-HBV drugs; research and development; guidelines
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kang, L.; Pan, J.; Wu, J.; Hu, J.; Sun, Q.; Tang, J. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses 2015, 7, 4960-4977.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top